The goal of this study was to determine whether rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), has any effect on delirium in vascular dementia (VaD). The results from this follow-up study suggest that although delirium is frequent in elderly, cognitively impaired patients, it might not be a simple consequence of acute disease and hospitalization. Rather, delirium can be secondary to brain damage and to metabolic disturbances. According to the Lewy body dementia model, delirium could be induced by a lack of acetylcholine in the brain. Rivastigmine may help reduce the frequency of delirium episodes and help shorten their duration. Additional studies are required to better define the causes of delirium, which currently has no definitive treatment.
Bourdel-Marchasson I, Vincent S, Germain C, et al.: Delirium symptoms and low dietary intake in older inpatients are independent predictors of institutionalization: A 1-year prospective populationbased study. J Gerontol A Biol Sci Med Sci.2004; 59(4): 350-354.
2.
Trzepacz PT: Update on the neuropathogenesis of delirium. Dement Geriatr Cogn Disord.1999; 10(5): 330-334.
3.
Miller BL, Josephson A: Cognitive manifestations of metabolic brain disease. American Academy of Neurology, 2003 Honolulu [lecture]. 5PC.005-5: 1-10.
4.
Rochat S, Camus V, Bula C: Acute confusional state in the elderly. Rev Med Suisse Romande.2003; 123(11): 685-689.
Burns A, Gallagley A, Byrne J: Delirium. J Neurol Neurosurg Psychiatry.2004; 75(3): 362-367.
7.
Cole MG: Delirum in elderly patients. Am J Geriatr Psychiatry. 2004; 12(1): 7-21.
8.
Caeiro L, Ferro JM, Albuquerque R, et al.: Delirium in the first days of acute stroke. J Neurol.2004; 251(2): 171-178.
9.
Román GC, Tatemichi TK, Erkinjuntti T, et al.: Vascular dementia: Diagnostic criteria for research studies. Report of the NINDSAIREN International Workshop. Neurology.1993; 43(2): 250-260.
10.
Wetterling T, Kanitz RD, Borgis KJ: The ICD-10 criteria for vascular dementia. Dementia.1994; 5(3-4): 185-188.
11.
Gottfries CG, Blennow K, Karlsson I, et al.: The neurochemistry of vascular dementia. Dementia.1994; 5(3-4): 163-167.
12.
Wallin A, Blennow K, Gottfries CG: Neurochemical abnormalities in vascular dementia. Dementia.1989; 1: 120-130.
13.
Togashi H, Kimura S, Matsumoto M, et al.: Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke.1996; 27(3): 520-525.
14.
Scremin OU, Li MG, Scremin AM, et al.: Cholinesterase inhibition improves blood flow in the ischemic cerebral cortex. Brain Res Bull.1997; 42(1): 59-70.
15.
Moretti R, Torre P, Antonello RM, et al.: Rivastigmine in subcortical vascular dementia: A comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol.2001; 8(4): 361-362.
16.
Moretti R, Torre P, Antonello RM, et al.: Rivastigmine in subcortical vascular dementia: An open 22-month study. J Neurol Sci. 2002; 203-204, 141-146.
17.
Moretti R, Torre P, Antonello RM, et al.: An open-label pilot study comparing rivastigmine and low-dose aspirin for the treatment of symptoms specific to patients with subcortical vascular dementia. Curr Ther Res.2002; 63(7): 443-458.
18.
Moretti R, Torre P, Antonello RM, et al.: Treatment of symptoms specific to patients with subcortical vascular dementia: An open 22 months study with Rivastigmine. Demencia.2003; 02: 1-6.
19.
Moretti R, Torre P., Antonello RM, et al.: Tratamiento de sintomas especificos en pacientes con demencia vascular subcortical: Un estudio abierto de rivastigmina de 22 meses de duracion. Demencia Hoy.2003; 10-14.
20.
Moretti R, Torre P., Antonello RM, et al.: Rivastigmine in subcortical vascular dementia: A randomized, controlled, open-12 month study in 208 patients. Am J Alzheimers Dis Other Demen.2003; 18(5): 265-272.
21.
Moretti R, Torre P, Antonello RM, et al.: Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: An open, 16-month, comparative study. Int J Clin Pract.2004; 58(4): 346-353.
22.
Erkinjuntti T, Bowler JV, DeCarli C, et al.: Imaging of static brain lesions in vascular dementia: Implications for clinical trials. Alzheimer Dis Assoc Disord.1999; 13Suppl 3: S81-S90.
23.
Hughes CP, Berg L, Ganziger WL, et al.: A new clinical scale for the staging of dementia. Br J Psychiatry.1982; 140: 566-572.
24.
Inouye SK, van Dyck Ch, Alessi CA, et al.: Clarifying confusion: The confusion assessment method. A new method for detection of delirium. Ann Intern Med.1990; 113(12): 941-948.
25.
Conwell Y, Forbes NT, Cox C, et al.: Validation of a measure of physical illness burden at autopsy: the Cumulative Illness Rating Scale. J Am Geriatr Soc.1993; 41(1): 38-41.
26.
Britton A, Russell R: Multidisciplinary team interventions for delirium in patients with chronic cognitive impairment. Multidisciplinary team interventions for delirium in patients with chronic cognitive impairment. Cochrane Database Syst Rev.2004(2): CD000395-CD000395.
27.
Kalaria RN, Ballard CG, Ince PG, et al.: Multiple substrates of late-onset dementia: Implications for brain protection. Novartis Found Symp.2001; 235: 49-60; discussion 60-65.
28.
Vennerica A, Shanks MF, Staff RT, et al.: Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport.2002; 13(1): 83-87.
29.
Sharma T, Kumari V, Mitterschiffthaler M, et al.: Cognitive effects of rivastigmine in Alzheimer's disease: An fMRI study. Poster presented at the American College of Neuropsychopharmacology 40th Annual Meeting. Waikoloa, Hawaii: December 9-13, 2001.
30.
Adler G, Brassen S: Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients. Neuropsychobiology. 2001; 43(4): 273-276.
31.
Potkin SG, Anand R, Fleming K, et al.: Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol.2001; 4(3): 223-230.
32.
Rombouts SA, Barkhof F, Van Meel CS, et al.: Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry.2002; 73(6): 665-671.
33.
Kaasinen V, Nagren K, Jarvenpaa T, et al.: Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol.2002; 22(6): 615-620.
34.
Lojkowska W, Ryglewicz D, Jedrzejczak T, et al.: The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J Neurol Sci.2003; 216(1): 119-126.
35.
Nordberg A, Stefanova E, Almkvist O, et al.: Improved cortical glucose metabolism in Alzheimer's disease (AD) patients treated with rivastigmine for 1 year. J Neurol Sci.2001; 187(Suppl 1): P0142-P0142.
36.
Almkvist O, Darreh-Shori T, Spiegel R, et al.: Improved cognition and plasma cholinesterase (ChE) inhibition in AD patients receiving rivastigmine for 1 year: Differential effects across time. J Neurol Sci. 2001; 187(Suppl 1): P0143-P0143.
37.
Nordberg A, Darreh-Shori T, Svensson A, et al.: Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in CSF of mild AD patients following 12 months of rivastigmine treatment. J Neurol Sci.2001; 187(Suppl 1): P0144-P0144.
38.
McKeith I, Del Ser T, Spano P, et al.: Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebocontrolled international study. Lancet.2000; 356(9247): 2031-2036.
39.
Harding AJ, Broe GA, Halliday GM: Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002; 125(Pt 2): 391-403.
40.
Reading PJ, Luce AK, McKeith IG: Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial. Mov Disord.2001; 16(6): 1171-1174.
